Features of Isoforms of Human Soluble TACI.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 07 2023
Historique:
received: 22 11 2021
accepted: 04 05 2023
medline: 5 7 2023
pubmed: 5 6 2023
entrez: 5 6 2023
Statut: ppublish

Résumé

The BAFF/APRIL-system with the two cytokines BAFF and APRIL and their three receptors, transmembrane activator and CAML interactor (TACI), BAFF receptor, and B-cell maturation Ag, is important for B cell maintenance. The BAFF/APRIL system is a therapeutic target in B cell-derived malignancies and autoimmune diseases. However, unexpected outcomes of clinical trials with atacicept (TACI-Fc) underline our incomplete understanding of this system. Shedding of the three receptors is one important regulatory element. In humans, TACI exists in two isoforms generated through alternative splicing in their extracellular portion: TACI-long (l) has two cysteine-rich domains, whereas TACI-short (s) lacks the first low-affinity one. In this study, we discriminated soluble (s) forms of TACI-l and TACI-s with newly generated mAbs and found that both were spontaneously released from activated human B cells, with a predominance of sTACI-l. Furthermore, sTACI-l was also the dominant isoform in human serum. Vaccination with the mRNA vaccine from BioNTech does not significantly affect the serum levels of sTACI-l. Both TACI-s and TACI-l were shed by a disintegrin and metalloproteinase domain-containing protein 10. TACI-l and TACI-s formed homo- and hetero-oligomers in soluble and membrane-bound forms. Both sTACI-l and sTACI-s acted as decoy receptors for BAFF, but only sTACI-l also efficiently inhibited APRIL. Dimerization of sTACI-l enhanced its decoy functions only slightly. Together, we extend our knowledge of the complexity of the BAFF/APRIL system by identifying and characterizing the two soluble isoforms of TACI.

Identifiants

pubmed: 37272840
pii: 263845
doi: 10.4049/jimmunol.2101107
doi:

Substances chimiques

B-Cell Activating Factor 0
B-Cell Activation Factor Receptor 0
Cytokines 0
Protein Isoforms 0
Transmembrane Activator and CAML Interactor Protein 0
Tumor Necrosis Factor Ligand Superfamily Member 13 0
TNFRSF13B protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-208

Informations de copyright

Copyright © 2023 by The American Association of Immunologists, Inc.

Auteurs

Miriam L Fichtner (ML)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.

Heike Rübsamen (H)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.

Michaela Smolle (M)

Physiological Chemistry, Biomedical Center, LMU Munich, Martinsried, Germany.
BioPhysics Core Facility, Biomedical Center, LMU Munich, Martinsried, Germany.

Jonas Schaller (J)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.

Regina Feederle (R)

Monoclonal Antibody Core Facility, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Andreas Bültmann (A)

MorphoSys AG, Planegg, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.

Pascal Schneider (P)

Department of Immunobiology, University of Lausanne, Lausanne, Switzerland.

Franziska S Thaler (FS)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Edgar Meinl (E)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH